BRIEF-NeuroVive Reports Progress In Clinical Project KL1333
Dec 11 (Reuters) - NEUROVIVE PHARMACEUTICAL AB:
* NEUROVIVE REPORTS PROMISING PROGRESS IN ITS CLINICAL PROJECT FOR GENETIC MITOCHONDRIAL DISEASES, KL1333
* - ‍PHARMACOKINETIC DATA WAS IN LINE WITH EXPECTATIONS AND NO ADVERSE SAFETY SIGNALS WERE DETECTED​
* ‍MULTIPLE-DOSE, PHASE IB STUDY IS PLANNED TO BE INITIATED IN EUROPE AND/OR U.S. IN 2018​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)